Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 9;14:2449–2461. doi: 10.2147/OTT.S286813

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Fu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) Inhibition of tumor growth by different formulations in a nasopharyngeal carcinoma-bearing xenograft model. The groups included an untreated control group and groups given empty nanoparticles, the free drugs (alone or in combination), and cisplatin- and afatinib-loaded lipid–polymer hybrid nanoparticles. All formulations were given intravenously every third day (three injections). The data are means ± standard deviation. (B) The tumor weights. The data are means ± standard deviations. *p<0.05, **p<0.01 and ***p<0.0001 is the statistical difference. (C and D) Histochemical analysis of tumor tissues treated with different formulations.